Company: LENZ
Filing Date: 2025-04-14
Form Type: 424B5
Source: 0001628280-25-017695
Chunk: 12

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-14
Form: 424B5
Chunk 12
---
 no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.

We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.

Other than a special cash dividend paid to our stockholders in connection with the Merger, we have never declared or paid cash dividends on shares of our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.

<div align='center'>S-8</div>

### SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This prospectus supplement includes and incorporates by reference “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section 27A of the Securities Act, and Section 21E of the Exchange Act. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements.

In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These forward-looking statements include, but are not limited to, statements about the following:

• the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates to the satisfaction of the Food and Drug Administration (“FDA”), and other positive results;

• the timing, scope and likelihood of regulatory approval for LNZ100;

• our ability to obtain and maintain regulatory approval of LNZ100;

• our plans relating to commercializing LNZ100, if approved, including the anticipated timing and geographic areas of focus and sales strategy;

• our plans relating to the development of LNZ100;

• the size of the market opportunity for LNZ100, including our estimates of the size of the affected population and potential adoption rate;

• our competitive position and the success of competing therapies that are or may become available;

• the beneficial characteristics, and the potential